news
Scottish Medicines Consortium approves Kymriah® CAR-T therapy
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
List view / Grid view
t-cells
news
Novel colorectal cancer vaccine shows positive phase I results
A new vaccine for colorectal cancer has proven to be safe in a small sample of human subjects, opening the way for the next phase of testing.
news
Regular infusions of a novel antibody may suppress HIV for four months
According to a new report, regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens.
news
Immunotherapy success for triple-negative breast cancer
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...
news
NHS announces groundbreaking personalised child cancer treatment
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
news
Anti-PD-1 therapy linked to delayed onset of skin disease
The onset of side effects of a common cancer treatment, anti-PD-1 therapy can be identified up to 3 years after treatment...
news
Neoantigen-based immunotherapy targets misshapen protein in DIPG
Children with an extremely deadly form of brain cancer may benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found on cancer cells...
news
TLR agonists suppress tumour growth
TLR agonists injected directly into a tumour suppresses tumour growth throughout the whole body...
news
Poliovirus therapy induces immune responses against cancer
Investigational therapy directly kills tumour cells and unmasks them to the body's defences.
news
Proposed guidelines for handling CAR-T cell side effects
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects...
news
Dolomite Bio offers flexible single cell encapsulation for autoimmune disease research
28 October 2016 | By Dolomite Bio
Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at…
news
First patient treated in Phase I VXM01 glioblastoma trial
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
news
Celyad and ONO strike deal for NKR-2 in Japan, Korea and Taiwan
11 July 2016 | By Victoria White, Digital Content Producer
This license agreement opens new markets to Celyad and expands the global footprint of its NKR-2 T-cell cancer immunotherapy treatment...
news
First patient treated in fourth dose level NKR-2 Phase I/IIa trial
23 June 2016 | By Victoria White, Digital Content Producer
The study is evaluating Celyad's NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma...
news
First patient treated in Phase I UCART19 trial in paediatric B-ALL
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
